APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Biodefense

Biodefense market refers to the pharmaceuticals, vaccines and antibodies applied in the treatment of a wide range of infectious diseases, whether those diseases emerge naturally or are deliberately introduced as an act of bioterrorism. Biodefense products generally defense against anthrax, smallpox, botulism, radiation/nuclear disasters and other disasters.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Biodefense market refers to the pharmaceuticals, vaccines and antibodies applied in the treatment of a wide range of infectious diseases, whether those diseases emerge naturally or are deliberately introduced as an act of bioterrorism. Biodefense products generally defense against anthrax, smallpox, botulism, radiation/nuclear disasters and other disasters.

In the wake of the 2001 anthrax attacks, the U.S. government set out on a bold path to improve the country’s preparedness for bioterrorism by developing and stockpiling new drugs and vaccines to protect Americans from health emergencies. Since 2004, the US government has provided assistance in the development and manufacturing of products in order to maintain its Strategic National Stockpile (SNS) to counter any bioterror attack.

Selected research

Market Outlook & Growth Opportunities

Global Biodefense Market Outlook and Growth Opportunities 2026

Report ID 17323308042 January 2026204 pages

Choose your research edition.

Industry ResearchBiodefense Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Biodefense Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Biodefense Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biodefense Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Biodefense Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

Biodefense market refers to the pharmaceuticals, vaccines and antibodies applied in the treatment of a wide range of infectious diseases, whether those diseases emerge naturally or are deliberately introduced as an act of bioterrorism. Biodefense products generally defense against anthrax, smallpox, botulism, radiation/nuclear disasters and other disasters.

In the wake of the 2001 anthrax attacks, the U.S. government set out on a bold path to improve the country’s preparedness for bioterrorism by developing and stockpiling new drugs and vaccines to protect Americans from health emergencies. Since 2004, the US government has provided assistance in the development and manufacturing of products in order to maintain its Strategic National Stockpile (SNS) to counter any bioterror attack.

The major players in global Biodefense market include Emergent Biosolutions, Hytest, GSK, etc. The top 3 players occupy about 60% shares of the global market. North America, Europe and Asia are key Regions of Sales. Anthrax and Smallpox are main types, with a share about 70%. US Civilian Market is the main application, which holds a share about 55%.

Read the full market overview

This report provides an overview of the global Biodefense market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biodefense and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biodefense revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Biodefense market.

Biodefense Segment by Company

Emergent Biosolutions

Hytest

GSK

Sanofi

PharmAthene

Bavarian Nordic

SIGA Technologies

Arbutus Biopharma

DynPort Vaccine

Xoma Corporation

Ichor Medical Systems

Aeolus Pharmaceuticals

Achaogen

Elusys Therapeutics

Dynavax Technologies

Cleveland BioLabs

Soligenix

Alnylam Pharmaceuticals

Biodefense Segment by Type

Anthrax

Smallpox

Botulism

Radiation/Nuclear

Others

Biodefense Segment by Application

US Military Market

US Civilian Market

Non - US Market

Biodefense Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Biodefense status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Biodefense key companies, revenue, market share, and recent developments.

3. To split the Biodefense breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Biodefense market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Biodefense significant trends, drivers, influence factors in global and regions.

6. To analyze Biodefense competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biodefense market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biodefense and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biodefense.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biodefense industry.

Chapter 3: Detailed analysis of Biodefense company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Biodefense in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Biodefense in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Biodefense Industry Trends Table 2. Biodefense Industry Drivers Table 3. Biodefense Industry Opportunities and Challenges Table 4. Biodefense Industry Restraints Table 5. Global Biodefense Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Biodefense Revenue Share by Company (2021-2026) Table 7. Global Biodefense Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Biodefense Key Company Manufacturing Base & Headquarters Table 9. Global Biodefense Company, Product Type & Application Table 10. Global Biodefense Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Biodefense by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Anthrax Table 15. Significant Companies of Smallpox Table 16. Significant Companies of Botulism Table 17. Significant Companies of Radiation/Nuclear Table 18. Significant Companies of Others Table 19. Global Biodefense Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Biodefense Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Biodefense Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Biodefense Sales Value Share by Type (2021-2026) Table 23. Global Biodefense Sales Value Share by Type (2027-2032) Table 24. Significant Companies of US Military Market Table 25. Significant Companies of US Civilian Market Table 26. Significant Companies of Non - US Market Table 27. Global Biodefense Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Biodefense Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Biodefense Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Biodefense Sales Value Share by Application (2021-2026) Table 31. Global Biodefense Sales Value Share by Application (2027-2032) Table 32. Global Biodefense Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Biodefense Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Biodefense Sales Value Share by Region (2021-2026) Table 35. Global Biodefense Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Biodefense Sales Value Share by Region (2027-2032) Table 37. Global Biodefense Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Biodefense Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Biodefense Sales Value Market Share by Country (2021-2026) Table 40. Global Biodefense Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Biodefense Sales Value Market Share by Country (2027-2032) Table 42. Emergent Biosolutions Company Information Table 43. Emergent Biosolutions Business Overview Table 44. Emergent Biosolutions Biodefense Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Emergent Biosolutions Biodefense Product Portfolio Table 46. Emergent Biosolutions Recent Development Table 47. Hytest Company Information Table 48. Hytest Business Overview Table 49. Hytest Biodefense Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Hytest Biodefense Product Portfolio Table 51. Hytest Recent Development Table 52. GSK Company Information Table 53. GSK Business Overview Table 54. GSK Biodefense Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. GSK Biodefense Product Portfolio Table 56. GSK Recent Development Table 57. Sanofi Company Information Table 58. Sanofi Business Overview Table 59. Sanofi Biodefense Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Sanofi Biodefense Product Portfolio Table 61. Sanofi Recent Development Table 62. PharmAthene Company Information Table 63. PharmAthene Business Overview Table 64. PharmAthene Biodefense Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. PharmAthene Biodefense Product Portfolio Table 66. PharmAthene Recent Development Table 67. Bavarian Nordic Company Information Table 68. Bavarian Nordic Business Overview Table 69. Bavarian Nordic Biodefense Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Bavarian Nordic Biodefense Product Portfolio Table 71. Bavarian Nordic Recent Development Table 72. SIGA Technologies Company Information Table 73. SIGA Technologies Business Overview Table 74. SIGA Technologies Biodefense Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. SIGA Technologies Biodefense Product Portfolio Table 76. SIGA Technologies Recent Development Table 77. Arbutus Biopharma Company Information Table 78. Arbutus Biopharma Business Overview Table 79. Arbutus Biopharma Biodefense Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Arbutus Biopharma Biodefense Product Portfolio Table 81. Arbutus Biopharma Recent Development Table 82. DynPort Vaccine Company Information Table 83. DynPort Vaccine Business Overview Table 84. DynPort Vaccine Biodefense Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. DynPort Vaccine Biodefense Product Portfolio Table 86. DynPort Vaccine Recent Development Table 87. Xoma Corporation Company Information Table 88. Xoma Corporation Business Overview Table 89. Xoma Corporation Biodefense Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Xoma Corporation Biodefense Product Portfolio Table 91. Xoma Corporation Recent Development Table 92. Ichor Medical Systems Company Information Table 93. Ichor Medical Systems Business Overview Table 94. Ichor Medical Systems Biodefense Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Ichor Medical Systems Biodefense Product Portfolio Table 96. Ichor Medical Systems Recent Development Table 97. Aeolus Pharmaceuticals Company Information Table 98. Aeolus Pharmaceuticals Business Overview Table 99. Aeolus Pharmaceuticals Biodefense Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Aeolus Pharmaceuticals Biodefense Product Portfolio Table 101. Aeolus Pharmaceuticals Recent Development Table 102. Achaogen Company Information Table 103. Achaogen Business Overview Table 104. Achaogen Biodefense Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Achaogen Biodefense Product Portfolio Table 106. Achaogen Recent Development Table 107. Elusys Therapeutics Company Information Table 108. Elusys Therapeutics Business Overview Table 109. Elusys Therapeutics Biodefense Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Elusys Therapeutics Biodefense Product Portfolio Table 111. Elusys Therapeutics Recent Development Table 112. Dynavax Technologies Company Information Table 113. Dynavax Technologies Business Overview Table 114. Dynavax Technologies Biodefense Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Dynavax Technologies Biodefense Product Portfolio Table 116. Dynavax Technologies Recent Development Table 117. Cleveland BioLabs Company Information Table 118. Cleveland BioLabs Business Overview Table 119. Cleveland BioLabs Biodefense Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Cleveland BioLabs Biodefense Product Portfolio Table 121. Cleveland BioLabs Recent Development Table 122. Soligenix Company Information Table 123. Soligenix Business Overview Table 124. Soligenix Biodefense Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Soligenix Biodefense Product Portfolio Table 126. Soligenix Recent Development Table 127. Alnylam Pharmaceuticals Company Information Table 128. Alnylam Pharmaceuticals Business Overview Table 129. Alnylam Pharmaceuticals Biodefense Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Alnylam Pharmaceuticals Biodefense Product Portfolio Table 131. Alnylam Pharmaceuticals Recent Development Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Biodefense Product Image Figure 2. Global Biodefense Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biodefense Market Size (2021-2032) & (US$ Million) Figure 4. Global Biodefense Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Anthrax Image Figure 8. Smallpox Image Figure 9. Botulism Image Figure 10. Radiation/Nuclear Image Figure 11. Others Image Figure 12. Global Biodefense Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Biodefense Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Biodefense Sales Value Share by Type (2021-2032) Figure 15. US Military Market Image Figure 16. US Civilian Market Image Figure 17. Non - US Market Image Figure 18. Global Biodefense Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Biodefense Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Biodefense Sales Value Share by Application (2021-2032) Figure 21. Global Biodefense Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Biodefense Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Biodefense Sales Value (2021-2032) & (US$ Million) Figure 24. North America Biodefense Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Biodefense Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Biodefense Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Biodefense Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Biodefense Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Biodefense Sales Value (2021-2032) & (US$ Million) Figure 30. South America Biodefense Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Biodefense Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Biodefense Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Biodefense Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Biodefense Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Biodefense Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Anthrax
  • Smallpox
  • Botulism
  • Radiation/Nuclear
  • Others
Applications
  • US Military Market
  • US Civilian Market
  • Non - US Market
Companies covered
  • Emergent Biosolutions
  • Hytest
  • GSK
  • Sanofi
  • PharmAthene
  • Bavarian Nordic
  • SIGA Technologies
  • Arbutus Biopharma
  • DynPort Vaccine
  • Xoma Corporation
  • Ichor Medical Systems
  • Aeolus Pharmaceuticals
  • Achaogen
  • Elusys Therapeutics
  • Dynavax Technologies
  • Cleveland BioLabs
  • Soligenix
  • Alnylam Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biodefense Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biodefense Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Biodefense Market Dynamics
  1. 2.1 Biodefense Industry Trends
  2. 2.2 Biodefense Industry Drivers
  3. 2.3 Biodefense Industry Opportunities and Challenges
  4. 2.4 Biodefense Industry Restraints
3 Biodefense Market by Company
  1. 3.1 Global Biodefense Company Revenue Ranking in 2025
  2. 3.2 Global Biodefense Revenue by Company (2021-2026)
  3. 3.3 Global Biodefense Company Ranking (2024-2026)
  4. 3.4 Global Biodefense Company Manufacturing Base and Headquarters
  5. 3.5 Global Biodefense Company Product Type and Application
  6. 3.6 Global Biodefense Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Biodefense Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Biodefense Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Biodefense Market by Type
  1. 4.1 Biodefense Type Introduction
  2. 4.1.1 Anthrax
  3. 4.1.2 Smallpox
  4. 4.1.3 Botulism
  5. 4.1.4 Radiation/Nuclear
  6. 4.1.5 Others
  7. 4.2 Global Biodefense Sales Value by Type
  8. 4.2.1 Global Biodefense Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Biodefense Sales Value by Type (2021-2032)
  10. 4.2.3 Global Biodefense Sales Value Share by Type (2021-2032)
5 Biodefense Market by Application
  1. 5.1 Biodefense Application Introduction
  2. 5.1.1 US Military Market
  3. 5.1.2 US Civilian Market
  4. 5.1.3 Non - US Market
  5. 5.2 Global Biodefense Sales Value by Application
  6. 5.2.1 Global Biodefense Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biodefense Sales Value by Application (2021-2032)
  8. 5.2.3 Global Biodefense Sales Value Share by Application (2021-2032)
6 Biodefense Regional Value Analysis
  1. 6.1 Global Biodefense Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biodefense Sales Value by Region (2021-2032)
  3. 6.2.1 Global Biodefense Sales Value by Region: 2021-2026
  4. 6.2.2 Global Biodefense Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biodefense Sales Value (2021-2032)
  7. 6.3.2 North America Biodefense Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Biodefense Sales Value (2021-2032)
  10. 6.4.2 Europe Biodefense Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Biodefense Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Biodefense Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Biodefense Sales Value (2021-2032)
  16. 6.6.2 South America Biodefense Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Biodefense Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Biodefense Sales Value Share by Country, 2025 VS 2032
7 Biodefense Country-level Value Analysis
  1. 7.1 Global Biodefense Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Biodefense Sales Value by Country (2021-2032)
  3. 7.2.1 Global Biodefense Sales Value by Country (2021-2026)
  4. 7.2.2 Global Biodefense Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Biodefense Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Biodefense Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Biodefense Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Biodefense Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Biodefense Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Biodefense Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Biodefense Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Biodefense Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Biodefense Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Biodefense Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Biodefense Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Biodefense Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Biodefense Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Biodefense Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Biodefense Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Biodefense Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Biodefense Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Biodefense Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Biodefense Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Biodefense Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Biodefense Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Biodefense Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Biodefense Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Biodefense Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Biodefense Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Biodefense Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Biodefense Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Biodefense Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Biodefense Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Biodefense Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Biodefense Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Biodefense Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Biodefense Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Biodefense Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Biodefense Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Biodefense Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Biodefense Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Biodefense Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Biodefense Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Biodefense Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Biodefense Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Biodefense Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Biodefense Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Biodefense Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Biodefense Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Biodefense Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Biodefense Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Biodefense Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Biodefense Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Biodefense Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Biodefense Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Biodefense Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Biodefense Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Biodefense Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Biodefense Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Biodefense Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Biodefense Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Biodefense Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Biodefense Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Biodefense Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Biodefense Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Biodefense Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Biodefense Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Biodefense Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Biodefense Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Biodefense Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Biodefense Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Biodefense Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Biodefense Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Biodefense Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Biodefense Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Biodefense Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Biodefense Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Biodefense Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Biodefense Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Biodefense Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Biodefense Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Biodefense Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Biodefense Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Biodefense Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Biodefense Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Biodefense Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Biodefense Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Biodefense Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Emergent Biosolutions
  2. 8.1.1 Emergent Biosolutions Company Information
  3. 8.1.2 Emergent Biosolutions Business Overview
  4. 8.1.3 Emergent Biosolutions Biodefense Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Emergent Biosolutions Biodefense Product Portfolio
  6. 8.1.5 Emergent Biosolutions Recent Developments
  7. 8.2 Hytest
  8. 8.2.1 Hytest Company Information
  9. 8.2.2 Hytest Business Overview
  10. 8.2.3 Hytest Biodefense Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Hytest Biodefense Product Portfolio
  12. 8.2.5 Hytest Recent Developments
  13. 8.3 GSK
  14. 8.3.1 GSK Company Information
  15. 8.3.2 GSK Business Overview
  16. 8.3.3 GSK Biodefense Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GSK Biodefense Product Portfolio
  18. 8.3.5 GSK Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Biodefense Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Biodefense Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
  25. 8.5 PharmAthene
  26. 8.5.1 PharmAthene Company Information
  27. 8.5.2 PharmAthene Business Overview
  28. 8.5.3 PharmAthene Biodefense Revenue and Gross Margin (2021-2026)
  29. 8.5.4 PharmAthene Biodefense Product Portfolio
  30. 8.5.5 PharmAthene Recent Developments
  31. 8.6 Bavarian Nordic
  32. 8.6.1 Bavarian Nordic Company Information
  33. 8.6.2 Bavarian Nordic Business Overview
  34. 8.6.3 Bavarian Nordic Biodefense Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bavarian Nordic Biodefense Product Portfolio
  36. 8.6.5 Bavarian Nordic Recent Developments
  37. 8.7 SIGA Technologies
  38. 8.7.1 SIGA Technologies Company Information
  39. 8.7.2 SIGA Technologies Business Overview
  40. 8.7.3 SIGA Technologies Biodefense Revenue and Gross Margin (2021-2026)
  41. 8.7.4 SIGA Technologies Biodefense Product Portfolio
  42. 8.7.5 SIGA Technologies Recent Developments
  43. 8.8 Arbutus Biopharma
  44. 8.8.1 Arbutus Biopharma Company Information
  45. 8.8.2 Arbutus Biopharma Business Overview
  46. 8.8.3 Arbutus Biopharma Biodefense Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Arbutus Biopharma Biodefense Product Portfolio
  48. 8.8.5 Arbutus Biopharma Recent Developments
  49. 8.9 DynPort Vaccine
  50. 8.9.1 DynPort Vaccine Company Information
  51. 8.9.2 DynPort Vaccine Business Overview
  52. 8.9.3 DynPort Vaccine Biodefense Revenue and Gross Margin (2021-2026)
  53. 8.9.4 DynPort Vaccine Biodefense Product Portfolio
  54. 8.9.5 DynPort Vaccine Recent Developments
  55. 8.10 Xoma Corporation
  56. 8.10.1 Xoma Corporation Company Information
  57. 8.10.2 Xoma Corporation Business Overview
  58. 8.10.3 Xoma Corporation Biodefense Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Xoma Corporation Biodefense Product Portfolio
  60. 8.10.5 Xoma Corporation Recent Developments
  61. 8.11 Ichor Medical Systems
  62. 8.11.1 Ichor Medical Systems Company Information
  63. 8.11.2 Ichor Medical Systems Business Overview
  64. 8.11.3 Ichor Medical Systems Biodefense Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Ichor Medical Systems Biodefense Product Portfolio
  66. 8.11.5 Ichor Medical Systems Recent Developments
  67. 8.12 Aeolus Pharmaceuticals
  68. 8.12.1 Aeolus Pharmaceuticals Company Information
  69. 8.12.2 Aeolus Pharmaceuticals Business Overview
  70. 8.12.3 Aeolus Pharmaceuticals Biodefense Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Aeolus Pharmaceuticals Biodefense Product Portfolio
  72. 8.12.5 Aeolus Pharmaceuticals Recent Developments
  73. 8.13 Achaogen
  74. 8.13.1 Achaogen Company Information
  75. 8.13.2 Achaogen Business Overview
  76. 8.13.3 Achaogen Biodefense Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Achaogen Biodefense Product Portfolio
  78. 8.13.5 Achaogen Recent Developments
  79. 8.14 Elusys Therapeutics
  80. 8.14.1 Elusys Therapeutics Company Information
  81. 8.14.2 Elusys Therapeutics Business Overview
  82. 8.14.3 Elusys Therapeutics Biodefense Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Elusys Therapeutics Biodefense Product Portfolio
  84. 8.14.5 Elusys Therapeutics Recent Developments
  85. 8.15 Dynavax Technologies
  86. 8.15.1 Dynavax Technologies Company Information
  87. 8.15.2 Dynavax Technologies Business Overview
  88. 8.15.3 Dynavax Technologies Biodefense Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Dynavax Technologies Biodefense Product Portfolio
  90. 8.15.5 Dynavax Technologies Recent Developments
  91. 8.16 Cleveland BioLabs
  92. 8.16.1 Cleveland BioLabs Company Information
  93. 8.16.2 Cleveland BioLabs Business Overview
  94. 8.16.3 Cleveland BioLabs Biodefense Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Cleveland BioLabs Biodefense Product Portfolio
  96. 8.16.5 Cleveland BioLabs Recent Developments
  97. 8.17 Soligenix
  98. 8.17.1 Soligenix Company Information
  99. 8.17.2 Soligenix Business Overview
  100. 8.17.3 Soligenix Biodefense Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Soligenix Biodefense Product Portfolio
  102. 8.17.5 Soligenix Recent Developments
  103. 8.18 Alnylam Pharmaceuticals
  104. 8.18.1 Alnylam Pharmaceuticals Company Information
  105. 8.18.2 Alnylam Pharmaceuticals Business Overview
  106. 8.18.3 Alnylam Pharmaceuticals Biodefense Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Alnylam Pharmaceuticals Biodefense Product Portfolio
  108. 8.18.5 Alnylam Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst